First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

ConferenceTransCon CNPPositive

AI Analysis

Summary

Ascendis Pharma presented first infant data from its TransCon CNP trial at ESPE 2026, showing stable or improved Achondroplasia Foramen Magnum Score at Week 52. The positive pediatric data supports the clinical development of the once-weekly CNP therapy for achondroplasia.

Clinical Trial Data

Primary Endpoint

Met

Importance:6/10

Sentiment:

0.65

achondroplasiapediatriconce-weeklyforamen magnumESPE 2026data presentation

Related Companies

$ASND

Read the original article

Published by GlobeNewswire Pharma on September 9, 2026 8:01 PM

Read Original